Cost utility of palivizumab prophylaxis among pre-term infants in the United States: A national policy perspective

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 987-996

  Mahadevia, Parthiv J ^a   Masaquel, Anthony S ^a,b   Polak, Mark J ^c   Weiner, Leonard B ^d  

^a MEDIMMUNE   (United States)

^b GENENTECH INC   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Cost effectiveness; Medicaid; Palivizumab; Private insurance; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; NEWBORN; PREMATURITY; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INSURANCE COVERAGE; INSURANCE, HEALTH; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84865246074     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.690013     Document Type: Review

References (46)

1. Synagis- (palivizumab). Full prescribing information. Gaithersburg, MD: MedImmune, LLC., 2011
2. Weiner LB, Masaquel AS, Polak MJ, et al. Cost-effectiveness analysis of palivizumab among preterm infant populations covered by Medicaid in the United States. J Med Econ 2012 Epub ahead of press
3. Data on File. Gaithersburg, MD: MedImmune, LLC
4. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry. J Perinatol 2008;28:511-7
5. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143:S12-32
6. Sangaré L, Curtis MP, Ahmad S. Hospitalization for respiratory syncytial virus among California infants: Disparities related to race, insurance, and geography. J Pediatr 2006;149:373-7
7. Shi N, Palmer L, Chu B-C, et al. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: A Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ 2011;14:335-40
8. Stewart DL, Romero JR, Buysman EK, et al. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin 2009;25:2795-804
9. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40
10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7
11. US Department of Labor. Consumer price index for all urban consumers (CPIU): US city average, by expenditure category and commodity and service group. http://www.bls.gov/news.release/cpi.t01.htm. Accessed April 19, 2012
12. Forbes ML, Hall CB, Jackson A, et al. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ 2010;13:136-41
13. Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr 2010;157:209-14
14. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-Analysis. Pediatr Crit Care Med 2011;12:580-8
15. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-9
16. Mullins CD, Seal B, Seoane-Vazquez E, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: The ISPOR Drug Cost Task Force report-Part IV. Value Health 2010;13:18-24
17. Thomson Healthcare, Inc. Red book drug topics. Montvale, NJ: PDR Network, LLC, 2010
18. Ortega-Sanchez IR. Cost-effectiveness of meningococcal vaccination in infants and toddlers in the United States. http://www.cdc.gov/vaccines/recs/ acip/downloads/mtg-slides-oct11/03-MCV-Ortega-Sanchez. pdf. Accessed January 12, 2012
19. Lanctot KL, Mitchell I, Paes BA, et al. CARESS: The Canadian registry of Synagis. Arch Dis Child 2008;93:ps97
20. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-80
21. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-6
22. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27
23. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61
24. Smart KA, Lanctot KL, Paes BA. The cost effectiveness of palivizumab: A systematic review of the evidence. J Med Econ 2010;13:453-63
25. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, et al. FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788-93
26. Simoes EA. RSV disease in the pediatric population: Epidemiology, seasonal variability, and long-term outcomes. Manag Care 2008;17:3-6, discussion 18-9
27. Stensballe LG, Fullarton JR, Carbonell-Estrany X, et al. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29:374-6
28. Fryzek JP, Martone WJ, Groothuis Jr. Trends in chronologic age and infant respiratory syncytial virus hospitalization: An 8-year cohort study. Adv Ther 2011;28:195-201
29. Hall CB, Walsh EE. Respiratory syncytial virus. Textbook of pediatric infectious diseases. Philadelphia, PA: WB Saunders, 2009. p 2462-87
30. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus-Associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012;31:5-9
31. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-Associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6
32. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98
33. Flaherman V, Li S, Ragins A, et al. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: A retrospective cohort study. Clin Ther 2010;32:2220-9
34. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694-701
35. National Summary of Medicaid Managed Care Programs and Enrollment. https://www.cms.gov/MedicaidDataSourcesGenInfo/downloads/2010Trends.pdf. Accessed March 12, 2012
36. Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16:46-58
37. Masaquel AS, Krilov LR, Wade SW, et al. Factors associated with non-compliance with palivizumab among Medicaid infants. Presented at: Pediatric Academic Societies Annual Meeting; April 28-May 1, 2012; Boston, MA
38. Krilov LR, Weiner LB, Wade SW, et al. Non-compliance with palivizumab and increased risk of respiratory syncytial virus hospitalization among a Medicaid population. Presented at: Pediatric Academic Societies Annual Meeting; April 28-May 1, 2012; Boston, MA
39. Gooch K, Busch K, Khong H. Length of hospital stay for respiratory syncytial virus in prophylaxed versus non-prophylaxed premature infants. Presented at: European Society for Paediatric Infectious Diseases; June 7-11, 2011; The Hague, The Netherlands
40. Palmer L, Hall CB, Katkin JP, et al. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol 2010;45:772-81
41. Paramore LC, Ciuryla V, Ciesla G, et al. Economic impact of respiratory syncytial virus-related illness in the US: An analysis of national databases. Pharmacoeconomics 2004;22:275-84
42. Paramore LC, Mahadevia PJ, Piedra PA. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr Pulmonol 2010;45:578-84
43. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics 2005;115:1536-46
44. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-76
45. Gold MR, Siegal JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
46. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151:34-42, 42.e.1